Abstract:The results of our study indicate low adherence to antiemetic guidelines in real‐world clinical practice in China. Only 8.1% of cisplatin‐based chemotherapy received the guideline compliant NK1RA‐5‐HT3RA‐glucocorticoid with or without olanzapine therapy when assessing antiemetic drugs administered, which may further reduce when evaluating dose, frequency, and duration. These findings highlight the importance of improving the management of CINV in China and provide useful information for better drug management. Background The current utilization of neurokinin‐1 receptor antagonists (NK1RAs) and the impact of updated guidelines on prescription patterns of antiemetic drugs among Chinese patients receiving highly emetogenic chemotherapy (HEC) remain undetermined. This study aims to analyze the present situation of Chinese cancer patients using antiemetic drugs and assess the appropriateness of antiemetic regimens. Methods Prescription data were collected between January 2015 and December 2020 from cancer patients receiving cisplatin‐based chemotherapy at 76 hospitals in six major cities in China. Trends in the use of antiemetic drugs, prescribing patterns and adherence to antiemetic guidelines were assessed. Results Among the 108,611 patients included in this study, 6 classes and 17 antiemetic drugs were identified as monotherapy or combination therapy in 93,872 patients (86.4%), whereas 14,739 patients (13.6%) were administered no antiemetic treatment. 5‐hydroxytryptamine 3 receptor antagonists (5‐HT3RAs) and glucocorticoids were the two most frequently used classes of antiemetics, followed by metoclopramide. NK1RAs were underused across the six cities, only 9332 (8.6%) and 1655 (1.5%) cisplatin‐based treatments were prescribed aprepitant and fosaprepitant, respectively. Prescriptions of olanzapine and lorazepam were very low throughout the study period. In prescribing patterns of antiemetic drugs, dual combination regimens were the most common (40.0%), followed by triple combination therapy and monotherapy (25.8% and 15.1%, respectively). Overall, the adherence to antiemetic guidelines for patients undergoing cisplatin‐based regimens was only 8.1% due to inadequate prescription of antiemetic drugs. Finally, our study also revealed that 5‐HT3RAs and glucocorticoids were overprescribed in 8.8% and 1.6% of patients, respectively. Conclusions The current study reveals suboptimal utilization of recommended antiemetic drugs for managing cisplatin‐based HEC‐induced nausea and vomiting in China. Improving the management of CINV is crucial, and these findings provide valuable insights into optimizing antiemetic drug practices.

Progress of Cisplatin Dose Adjustment Based on the Renal Function

Progress of Cisplatin Pharmacokinetics Research

Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation

Validity of renal function eligibility criteria for cisplatin-based chemotherapy for patients with urothelial carcinoma.

Cisplatin-Induced Renal Failure Measured by Glomerular Filtration Rate (GFR) with 99mTc-DTPA Scans in Cancer Patients: A Systematic Review and Meta-Analysis

[Effects of Fractionated Low Dose Cisplatin on Renal Functions of Patients with Gastric Carcinoma].

Monitoring of the renal function changes during chemotherapy based on high-dose cisplatin in patients with lung cancer

Clinical pharmacist’s involvement in treatment adjustment of a senior small cell lung cancer patient with renal insufficiency：a case analysis

Mitochondrial Dysfunction at the Early Stage of Cisplatin-Induced Acute Renal Failure in Rats

Cisplatin nephrotoxicity: new insights and therapeutic implications

Advances in Toxicological Research of the Anticancer Drug Cisplatin

Cisplatin-induced renal toxicity in elderly people

Aging increases the susceptibility of cisplatin-induced nephrotoxicity

Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity

Pretreatment of Huaiqihuang Extractum Protects Against Cisplatin-Induced Nephrotoxicity

Research progress on the premature ovarian failure caused by cisplatin therapy

Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Histone deacetylases: potential therapeutic targets in cisplatin-induced acute kidney injury

The toxicity of cisplatin derives from effects on renal organic ion transporters expression and serum endogenous substance levels

Diurnal variation of cisplatin-induced renal toxicity in ICR mice

Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury